Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
NCT07080905
Recruiting
This is a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participants with severe or moderately severe hemophilia B.
Gender:
MALE
Ages:
Between 138 months and 206 months
Trial Updated:
08/04/2025
Locations: University of Florida - 84000399, Gainesville, Florida +1 locations
Conditions: Hemophilia B
Register for Updates
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
NCT07054515
Recruiting
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in late-infantile and juvenile-onset forms of GM1 gangliosidosis or GM2 gangliosidosis
Gender:
ALL
Ages:
4 years and above
Trial Updated:
08/04/2025
Locations: Children's Hospital and Research Center at Oakland, Oakland, California +31 locations
Conditions: Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
Register for Updates
This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.
NCT07115017
Recruiting
This study involves a Positron Emission Tomography (PET) scan using a new investigational radioactive tracer, \[18F\]-FZTA, to detect inflammation in the brain. The tracer will be tested in healthy younger adults and individuals with Multiple Sclerosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Washington University in St. Louis, Saint Louis, Missouri
Conditions: Multiple Sclerosis
Register for Updates
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
NCT07116889
Recruiting
This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/04/2025
Locations: Alcanza, DeLand, Florida +12 locations
Conditions: Asthma, COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
Inspire UAS High Apnea Hypopnea Index (AHI)/High Body Mass Index (BMI) Post-Approval Study
NCT07113288
Recruiting
The purpose of this observational clinical study is to provide evaluation of long-term safety and effectiveness in a newly expanded patient population including patients with a higher AHI and a higher BMI.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Colorado ENT & Allergy, Colorado Springs, Colorado +4 locations
Conditions: Obstructive Sleep Apnea (OSA)
Register for Updates
Assessing Claims of Cannabis as an Anti-cancer Agent (CATA)
NCT07107607
Recruiting
The purpose of the study is to find out how cannabis may help control cancer growth by reviewing medical records of patients who report cannabis helped treat their cancer.
Gender:
ALL
Ages:
All
Trial Updated:
08/04/2025
Locations: HealthPartners Institute Cancer Research Center, Saint Louis Park, Minnesota
Conditions: Cancer, Cancer (With or Without Metastasis)
Register for Updates
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
NCT06350318
Recruiting
The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma
Register for Updates
Speech Understanding and Listening Effort Benefits of Hearing Instruments
NCT07116135
Recruiting
The goal of this clinical study is to investigate the benefits of hearing instrument use in adults with hearing loss. The main questions it aims to answer are: Does hearing instrument use improve speech understanding and listening effort amount people with hearing loss? Researchers will compare varying models of hearing instruments to see how speech understanding and listening effort are impacted. Participants will be asked to wearing varying hearing instruments and participate in lab-based ac... Read More
Gender:
ALL
Ages:
Between 18 years and 95 years
Trial Updated:
08/04/2025
Locations: University of South Florida Auditory Neurosciences & Technology Lab, Tampa, Florida
Conditions: Hearing Loss, Bilateral
Register for Updates
Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism
NCT07091279
Recruiting
The goal of this clinical trial is to learn if propranolol can help reduce challenging behaviors associated with Autism Spectrum Disorder, including aggression, self-injury, and severe disruptive behaviors. Participants will be randomly assigned to receive either propranolol or a placebo (a look-alike substance that contains no drug) daily for 12 weeks. After the 12 weeks, all participants will have the opportunity to receive propranolol for an additional 12 weeks.
Gender:
ALL
Ages:
Between 12 years and 40 years
Trial Updated:
08/04/2025
Locations: New York State Institute for Basic Research (IBR), Staten Island, New York +1 locations
Conditions: Autism Spectrum Disorder, Challenging Behaviour, Aggression, Severe Disruptive Behaviour Disorders, Self-injury
Register for Updates
Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders
NCT07043803
Recruiting
The goal of this study is to reduce Anticholinergic Medication (ACM) in persons with psychoses or serious mental illness, when these medications are no longer needed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Western Behavioral Health of the Alleghenies, Altoona, Pennsylvania +3 locations
Conditions: Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychiatric Disorders
Register for Updates
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319
Recruiting
This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic treatments. Study details include: * The study duration will be approximately 64 weeks for participants not transiti... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/04/2025
Locations: The Center for Clinical Trials - Saraland- Site Number : 8400096, Saraland, Alabama +205 locations
Conditions: Asthma
Register for Updates
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
NCT07038876
Recruiting
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syn... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
08/04/2025
Locations: Clinical Site, Little Rock, Arkansas +24 locations
Conditions: Schizophrenia
Register for Updates